MRD testing is crucial for high-risk MM patients, aiding in early detection and treatment decisions, despite logistical and insurance barriers. Physicians primarily use MRD to monitor remission, ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
Molecular residual disease, or MRD, testing is emerging as a powerful tool in breast cancer, offering new visibility into what traditional imaging cannot detect. 1 MRD tests, like the Oncodetect® test ...
April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Minimal residual disease (MRD) testing is poised to transform cancer care, according to John Truesdell, Chief Business Officer at Foresight Diagnostics. In a recent interview with Fierce, Truesdell ...
MRD testing showed weak trial-level correlation with progression-free survival in BTK inhibitor and venetoclax-based CLL studies.
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading ...
Roche has agreed to acquire molecular residual disease (MRD) specialist, Saga Diagnostics and its platform in a $595m bid – further expanding its cancer monitoring portfolio. This merger will see ...
Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares jumped 10% after the company announced strategic agreements with Fidelion Diagnostics to jointly commercialize VitaGuard, a next-generation liquid biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results